The Europe GLP-1 agonists market, valued at USD 7.09 billion in 2024, is set to grow at a 17.30% CAGR, reaching USD 14.34 billion by 2034. Driven by ...

Explore the growing GLP-1 agonists market, driven by rising diabetes and obesity rates. Discover advancements in therapies like Tirzepatide and GZR18 ...

GLP-1 receptor agonists such as semaglutide and liraglutide promote significant weight loss and improved glycemic control, ...

Researchers have determined in a new study that the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) lower the risk of ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

Data from a limited number of trials hint that GLP-1 use might improve erectile dysfunction and testosterone levels for men, but more research is needed to provide a clearer picture, researchers ...

Tirzepatide reduces breast tumor growth in obese mice while improving metabolic health, offering hope as a dual-action cancer ...

New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

rs6190 helps men build muscle mass and reduce diabetes risk, but increases cholesterol levels and elevates the risk of ...

Scientists have gene-hacked mice to produce their own Ozempic-like drugs, paving a path for humans to do so themselves one ...

AAP FactCheck - A Facebook page promoting weight loss products is falsely claiming a supposedly New Zealand-made patch has ...

A FAT jab user has revealed that after stopping the injections for eight weeks, she has now realised she is a “Mounjaro lifer ...